The Same Failure, Twice: What CIHR's New Strategy and the Collapse of US-Canada Trade Talks Have in Common

On August 22, 2026, trade talks between Canada and the United States collapsed hours before a deadline, and 50% US tariffs hit a wide range of Canadian goods at 12:01 a.m. Canada's retaliatory tariffs take effect September 8. USMCA remains unrenewed in its current form. Whatever happens next in that negotiation, one thing is already clear: Canada just had a real-time demonstration of what it means to depend on another country for something essential.

Sixteen days earlier, and with far less attention, the Canadian Institutes of Health Research quietly published a new Knowledge Mobilization Strategy and Action Plan, the federal blueprint for how Canada's health research funding agency will move discoveries into real-world use over the coming years. On the surface, these are two unrelated stories: one is a trade dispute, the other is a research-funding document. Underneath, they are describing the exact same national weakness from two different vantage points, one measured in lost economic opportunity, the other now measured in exposure to a supply shock.

What the CIHR Document Actually Reveals

The strategy explicitly defines commercialization and industry collaboration as a valued, in-scope form of knowledge mobilization, quoting its own definition: "the process focused on bringing intellectual property, new products, tools, or services, to a state of use in the private, not-for-profit, or public sectors." That's the correct definition.

But scan the entire action plan, all four of its work streams, Enhance, Transform, Invest, and Learn, and not a single funded action item is commercialization-specific. Instead, CIHR states, twice, once in the executive summary and again in its closing paragraph, that a separate "Commercialization and Industry Collaboration Strategy and Action Plan" will be forthcoming. No publication date is attached either time.

That's the pattern that keeps getting repeated: name the hardest, highest-stakes part of the pipeline as important, then defer it to a future document that doesn't yet exist, twice, for emphasis. Responsibility gets acknowledged and simultaneously postponed.

This matters more than one missing chapter suggests. Buried elsewhere in the same document is a statistic that should stop every health system executive in the country: a systematic review of 174 studies, covering 228 clinical practices and 28 million Canadians, found the median rate of inappropriate clinical care in Canada to be 30%. Roughly three out of every ten patients are not receiving appropriate care, not because the science doesn't exist, but because the system fails to adopt the breakthroughs Canadian taxpayers already funded. Industry collaboration, the thing this strategy defers, is one of the few mechanisms that reliably closes that exact gap.

Three further patterns confirm this isn't an isolated oversight. Every action item in the plan is timed as Short-term (1–2 years), Medium-term (3–5 years), Ongoing (continuous focus), or Conditional (resource-dependent), with no calendar date and no individually accountable owner anywhere in the document. Success is measured through what the strategy calls "dissemination effectiveness," webinars delivered, papers published, plain-language summaries produced, not companies formed, not patients treated. And while CIHR candidly admits the absence of "dedicated, adequate and consistent funding for KM practice" as a theme from its own consultations, every new program it funds in response sits inside the same streams that contain zero commercialization-specific actions. New money flows to the part of the pipeline Canada already does reasonably well, while the part explicitly deferred remains unfunded and undated.

What This Looks Like Inside an Actual Hospital

The CIHR document is abstract. The failure it describes is not. Canadian hospital purchasing runs largely through Shared Services Organizations and Group Purchasing Organizations, entities like Plexxus or Mohawk Medbuy, built and optimized to buy high-volume commoditized goods at the lowest possible price. They are not built to evaluate a novel diagnostic or therapeutic on its total economic and clinical value, which means a genuinely superior Canadian innovation is, structurally, fighting the wrong kind of battle to get purchased at all.

Even a fully approved therapy can hit a wall well past that point. Novartis Canada is not a company retreating from the country: it maintains roughly 500 employees and invests over $36 million annually in Canadian R&D. Yet on July 13, 2026, Health Canada approved Novartis's Vanrafia (atrasentan) for proteinuria reduction in adults with a serious kidney disease, IgA nephropathy, based on an interim Week 36 analysis of the Phase III ALIGN trial. Five weeks later, Novartis Canada confirmed to media it would not pursue public reimbursement for the drug, citing only "the current access environment." No more specific reasoning has been made public. Canadian patients now have a Health Canada-approved therapy that isn't publicly accessible, and no formal record of exactly why.

This isn't an isolated anecdote. It's consistent with a broader, independently documented pattern: CDA-AMC's own published data show that between 2020 and 2024, an average of only about 48.5% of new Health Canada drug approvals were ever submitted for reimbursement review at all. Roughly half of approved drugs, therapies Canadians' own tax dollars helped fund through the research and regulatory pipeline, never even enter the process that would make them publicly accessible. A drug that never enters the reimbursement process leaves no formal decision record behind it, which means accountability for the outcome effectively evaporates.

A parallel pattern shows up in medical devices. Since 2019, Canada has been the only country among the five MDSAP-participating nations, Australia, Brazil, Canada, Japan, and the US, to make the Medical Device Single Audit Program mandatory rather than voluntary or simply recognized. One Canadian medical device founder has described watching a Canadian-developed device pushed out of the domestic market by the resulting compliance costs, even as the same device continued to be used successfully overseas. That's a variant of the export-and-buy-back pattern worth naming precisely: not funding the discovery, losing the company, then repurchasing the finished product at a premium, but something quieter and more permanent, a Canadian-made product simply becoming unavailable to Canadians altogether. Call it export-and-never-buy-back.

Why These Are the Same Failure

The connective tissue is this: Canada consistently funds discovery and consistently defers, indefinitely, the harder, more capital-intensive, more accountability-heavy work of building the commercial and manufacturing capacity to act on that discovery.

This imbalance shows up directly in how Canadian companies allocate capital relative to their US peers. Charles Plant's C.D. Howe Institute analysis found that Canadian scaling firms spend 29.6% of revenue on R&D against 25.2% in the US, while spending only 35.8% on sales and marketing against 46.8% in the US, despite posting steeper net losses as a share of revenue (42.2% versus 28.3% for US firms). The same analysis found that federal budget documents between 2012 and 2022 mentioned "research and innovation" 34 times more often than "commercialization." Canada's federal R&D credit, SR&ED, subsidizes technical research directly, and no equivalent federal credit exists for commercialization or go-to-market spend. Plant's own recommendation is direct: reduce R&D credits and redirect the savings toward funding marketing and sales development instead.

The capital gap compounds this. Canada produces roughly 0.81 startups with a $1 billion enterprise valuation per million people, compared to 1.8 in the US and 5.6 in Israel, this despite Canada spending over $4 billion a year on R&D tax credits like SR&ED. Canadian life sciences venture funds average $150–300 million in size and typically write $10–20 million cheques, enough to carry a company through early rounds but far short of what a late-stage scale-up needs, which is a structural reason Canadian pension capital, despite actively investing in life sciences abroad, allocates comparatively little domestically: no domestic fund is large enough to absorb a pension-scale cheque.

This is the same institutional reflex that let Canada sell Connaught Laboratories, the institution that manufactured insulin domestically at near cost for 65 years after its discovery at the University of Toronto. Today Canada manufactures none of its own insulin, importing it instead from Denmark, France, and Germany. The foundational biology behind GLP-1 drugs like Ozempic was discovered by Dr. Daniel Drucker at the University of Toronto and Sinai Health's Lunenfeld-Tanenbaum Research Institute, while the commercial and manufacturing value belongs to Novo Nordisk, in Denmark. Canada has proven, twice, that it can build durable domestic health manufacturing capacity. Both times, that capacity was deliberately let go for short-term reasons.

Today, Canada's pharmaceutical supply chain is almost entirely dependent on foreign capacity. Roughly 80% of the world's active pharmaceutical ingredients, the raw material inside both brand-name and generic medicines, are manufactured in China and India. Canada's reliance on imported pharmaceutical products has grown from 74% to 93% of total domestic drug expenditures over the past decade. Health Canada has already identified 157 drugs, out of roughly 9,000 marketed in the country, that are both critical to patients and vulnerable to shortage, on its Critical and Vulnerable Drug List. That list exists because the government already knows how fragile this is. What doesn't exist is a domestic production base to back it up.

Now overlay the events of the past two weeks. A trading partner Canada has relied on for decades just imposed 50% tariffs after negotiations collapsed, with retaliation set to follow. If medicine, rather than steel or dairy, becomes the next flashpoint in a trade dispute, or if a supply disruption originates somewhere else entirely, Canada would be negotiating from a position with almost no domestic manufacturing leverage to fall back on.

Before the events of the past two weeks, this reflex was primarily an economic opportunity cost, lost jobs, lost company value, foreign buyouts at a premium. After the events of the past two weeks, it is also a resilience cost, measured in exactly how exposed Canada is the moment a supply relationship becomes politically unstable.

What Would Actually Address Both

Fixing the commercialization gap and fixing the health sovereignty gap are not two separate policy agendas. They are the same fix, applied at different points in the same pipeline:

1. Give CIHR's deferred commercialization strategy a fixed, date-stamped deadline, not a twice-repeated open-ended "forthcoming." A commitment without a date is not a commitment, and this is the earliest point in the pipeline where the pattern could be broken.

2. Sync federal research and health funding metrics to real-world implementation and domestic manufacturing capacity, not publication volume or pilot completion. A validated Canadian discovery that never becomes a Canadian-manufactured product is not, by any real measure, a success.

3. Fund the adopter's side of the equation directly: hospitals need flexible operating budgets to purchase and implement Canadian innovation, and Budget 2026 has a genuine opening to treat pharmaceutical manufacturing capacity as critical infrastructure, the same way Canada already treats energy and defence production.

4. Track which of Health Canada's 157 critical and vulnerable drugs Canada could plausibly produce domestically, and treat that list as a starting inventory for targeted manufacturing investment, not just a monitoring exercise.

5. Structure future commercialization incentives around outcome-based milestones, not self-attestation. Any matching credit designed to correct the R&D-to-marketing imbalance needs to be structured to comply with Canada's WTO obligations, meaning eligibility tied to the underlying activity itself rather than export status, and to avoid the verification weaknesses that have historically let firms reclassify existing spend as qualifying activity under programs like SR&ED. Eligibility should rest on independently verifiable outcomes, such as net-new customer contracts or documented market entry, not self-reported activity.

We cannot build a resilient health system, or a competitive life sciences economy, on the returns of research that never leaves the page, or on a supply chain that runs entirely through capacity Canada doesn't control. The past two weeks made that exposure concrete. The CIHR strategy shows the exposure was never really about trade policy in the first place. It's about whether Canada is willing to fund the unglamorous, capital-intensive work of turning what it already knows how to do into something it actually builds, keeps, and controls.